Genocea Biosciences Inc Book/Share
What is the Book/Share of Genocea Biosciences Inc?
The Book/Share of Genocea Biosciences Inc is 0.00
What is the definition of Book/Share?
Book value per share is a company’s assets minus liabilities divided by the number of shares outstanding.
mrq (most recent quarter)
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Book/Share of companies in the Health Care sector on NASDAQ compared to Genocea Biosciences Inc
What does Genocea Biosciences Inc do?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Companies with book/share similar to Genocea Biosciences Inc
- Cycliq has Book/Share of 0.00
- B. Riley Principal Merger II has Book/Share of 0.00
- FG Acquisition has Book/Share of 0.00
- Nexway AG has Book/Share of 0.00
- THC Therapeutics has Book/Share of 0.00
- Thoma Bravo Advantage has Book/Share of 0.00
- Genocea Biosciences Inc has Book/Share of 0.00
- Canada Rare Earth has Book/Share of 0.00
- Galilee has Book/Share of 0.00
- PT Aneka Tambang Tbk has Book/Share of 0.00
- Coho Collective Kitchens has Book/Share of 0.00
- My Rewards International Ltd has Book/Share of 0.00
- Six Sigma Metals has Book/Share of 0.00